The investors in Cytokinetics, Incorporated's (NASDAQ:CYTK) will be rubbing their hands together with glee today, after the share price leapt 26% to US$74.84 in the week following its first-quarter results. Revenues of US$19m beat estimates by a substantial 119% margin. Cytokinetics also reported a statutory loss of US$1.67 per share, which was roughly in line with what the analysts predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

After the latest results, the consensus from Cytokinetics' 17 analysts is for revenues of US$97.6m in 2026, which would reflect a perceptible 7.7% decline in revenue compared to the last year of performance. The loss per share is expected to ameliorate slightly, reducing to US$6.51. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$92.9m and losses of US$6.51 per share in 2026.

The consensus price target rose 9.2% to US$102, with the analysts encouraged by the improved revenue outlook even though the company remains lossmaking. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Cytokinetics analyst has a price target of US$146 per share, while the most pessimistic values it at US$69.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. Over the past five years, revenues have declined around 5.5% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 10% decline in revenue until the end of 2026. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 21% annually. So while a broad number of companies are forecast to grow, unfortunately Cytokinetics is expected to see its revenue affected worse than other companies in the industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Cytokinetics going out to 2028, and you can see them free on our platform here.

Even so, be aware that Cytokinetics is showing 3 warning signs in our investment analysis , and 1 of those is significant...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.